ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1685275
Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE
Provisionally accepted- 1Charite - Universitatsmedizin Berlin Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Berlin, Germany
- 2Charite - Universitatsmedizin Berlin Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin - Campus Charite Mitte, Berlin, Germany
- 3Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
- 4Universidad de Antioquia Grupo de Inmunologia Celular e Inmunogenetica, Medellín, Colombia
- 5Immanuel Krankenhaus Berlin Standort Berlin-Wannsee, Berlin, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and the involvement of multiple organ systems. The disease's heterogeneity challenges clinical assessment, highlighting the need for personalized diagnostics and therapies. Soluble immune checkpoint molecules (sICPs) have emerged as potential biomarkers for predicting disease activity in other autoimmune diseases. However, the role of sICPs in SLE has not yet been delineated. In this study serum concentrations of soluble co-stimulatory (sCD25, sCD27, sCD40L, s4-1BB and sCD86) and co-inhibitory checkpoint molecules (sCTLA-4, sPD-1, sPD-L1, sPD-L2, sTim-3, sGal-9 and sLAG-3) were measured by bead-based assay in 235 SLE patients. sICPs were analyzed in relation to clinical data (SLEDAI, organ involvement, C3, C4, anti-dsDNA, Siglec-1, and sustained DORIS/LLDAS remission). Analyses included Wilcoxon rank-sum tests, multivariable logistic regressions, receiver operating characteristic (ROC) analyses, cluster analyses, and correlation matrices. Higher concentrations of sCD25, sTim-3, and sGal-9 were associated with active SLE disease (SLEDAI > 4). Cluster analysis identified highest concentrations in a SLE subgroup with more severe disease (median SLEDAI 10). These molecules correlated strongly with each other and were specifically elevated in patients with renal involvement and/or anemia, but not with APS, skin, or joint manifestations. This study highlights sCD25, sTim-3, and sGal-9 as biomarkers for active SLE and renal and hematologic involvement. Low sCD25 levels were associated with achieving long-term DORIS and LLDAS remission, underscoring the potential of sCD25 as a predictive and sensitive biomarker mandating further clinical validation.
Keywords: SLE, biomarker, Soluble immune checkpoints, remission, activity, SLEDAI
Received: 13 Aug 2025; Accepted: 03 Sep 2025.
Copyright: © 2025 Dreveton, Spencker, Rincon-Arevalo, Aue, Osmanodja, Wiedemann, Szelinski, Krönke, Dörner, Schrezenmeier and Stefanski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Léa-Sophie Dreveton, Charite - Universitatsmedizin Berlin Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Berlin, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.